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Abstract
Background: Polycystic ovary syndrome (PCOS) is a reproductive-metabolic condition. Insulin resistance is a
hallmark of PCOS and is related to increased hyperandrogenism that drives inherent metabolic, reproductive
and psychological features of the syndrome. Insulin resistance in women with PCOS is managed by weight
loss, lifestyle interventions (i.e. exercise, diet) and insulin-sensitising medications. This manuscript describes the
protocol of our study evaluating the effectiveness of high intensity intermittent training (HIIT) or moderate
intensity exercise on cardiometabolic, reproductive and mental health in overweight women with PCOS.
Methods/design: We will employ a three arm, parallel-group, randomised controlled trial recruiting 60 women
diagnosed with PCOS, aged between 18 and 45 years and with a body mass index (BMI) greater than 25 kg/m2.
Following screening and baseline testing, women will be randomised by simple randomisation procedure using
computer generated sequence allocation to undergo one of two 12-week supervised interventions: either HIIT or
moderate intensity exercise (standard supervised exercise), or to standard care [Con] (unsupervised lifestyle advice) at a
1:1:1 allocation ratio. The primary outcome for this trial is to measure the improvements in metabolic health; specifically
changes in insulin sensitivity in response to different exercise intensities. Baseline and post-intervention testing include
anthropometric measurements, cardiorespiratory fitness testing, reproductive hormone profiles (anti-müllerian
hormone and steroid profiles), metabolic health, health-related quality of life and mental health questionnaires
and objective and subjective lifestyle monitoring. Reporting of the study will follow the CONSORT statement.
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Discussion: This trial aims to demonstrate the comparative efficacy and maintenance of different exercise
intensities to advance the understanding of PCOS management and provide insight into the optimal exercise
intensity for improved cardiometabolic outcomes. Secondary outcomes will include the impact of different
exercise protocols on reproductive hormone profiles, mental health and health-related quality of life.
Trial registration: Australian New Zealand Clinical Trials Registry, ACTRN12615000242527. Registered on 17
March 2015.
Keywords: Polycystic ovary syndrome, High-intensity interval training, Cardiorespiratory fitness, Cardiometabolic
health, Insulin, Mental health, Overweight, Exercise, Exercise therapy
Background
Polycystic ovary syndrome (PCOS) is a major public
health concern affecting 6–10% of reproductive-aged
women worldwide [1]. Insulin resistance is strongly im-
plicated in the aetiology of PCOS and is associated with
the reproductive and metabolic consequences of the syn-
drome [2–7]. Insulin resistance in PCOS is inherent and
has been demonstrated to be independent of body mass
index (BMI), yet can be exacerbated by obesity [2, 8], al-
though the mechanisms remain unclear. Lifestyle inter-
ventions (diet, exercise and/or behavioural) and weight
management are the first line therapy [9] for women
with PCOS as they improve the clinical symptoms by in-
creasing insulin sensitivity in these women [4, 10].
Moderate intensity aerobic exercise improves meta-
bolic and reproductive features, body composition and
psychological well-being in overweight women with
PCOS [4, 11, 12]. However, even after exercise interven-
tions a higher level of insulin resistance prevails in
women with PCOS compared to women without PCOS,
indicating further research is warranted [4]. High inten-
sity interval training (HIIT) is a popular fitness program
that encompasses short bouts of high intensity exercise
interspersed with active recovery [13]. HIIT has been
shown to be acceptable and safe and may assist in ad-
dressing barriers reported in women of reproductive age,
including time limitations and competing commitments
and PCOS-specific barriers such as low confidence and
physical limitations [14, 15]. HIIT is enjoyable [4, 16–
18] and has been found to have a superior effect on in-
sulin resistance, cardiovascular risk factors and all-cause
mortality amongst other predominantly male and older
clinical populations [19–22]. Despite this, there is lim-
ited comprehensive research on the efficacy of different
exercise intensities and optimal exercise intensity for im-
proved cardiometabolic outcomes, reproductive hor-
mone profiles, mental health and health-related quality
of life following exercise in PCOS.
Compared to recommended lower-intensity regimes,
more positive metabolic health outcomes are now being
reported for HIIT, including improved glycaemic control
and cardio-respiratory fitness in clinical populations and
amongst women with PCOS [17, 18, 22–24]. Only one
randomised controlled trial (RCT) has been conducted
in women with PCOS to assess the benefits of HIIT, in
which they compared a resistance-training program and
a control group [18]. After 10 weeks, they found im-
provements in insulin sensitivity and high-density lipo-
protein cholesterol and a decrease in fat percentage [18].
A cross-sectional study conducted by Greenwood et al.
[23] was the first to examine the effect of exercise of
varying intensities amongst women with PCOS. The re-
sults of their study supported superior health benefits of
vigorous exercise, including a lower BMI and Homeo-
static Model Assessment of Insulin Resist-
ance (HOMA-IR) and higher levels of high-density
lipoprotein and sex hormone binding globulin compared
with moderate exercise in women with PCOS, independ-
ent of age, BMI and total exercise volume [23]. Specific-
ally, it was found that 60 min of vigorous activity per
week was associated with a 22% reduction in the odds
ratio of metabolic syndrome (1.11; 95% confidence inter-
val 1.04, 1.18) [23]. Although these studies provide posi-
tive results in favour of high intensity exercise, more
objective data and further investigation are required to
find the optimal intensity in promoting the greatest
health benefits for women with PCOS. Therefore, the
aim of this protocol paper is to detail an exercise inter-
vention that explores the clinical effectiveness and effi-
cacy of HIIT compared to moderate intensity exercise or
standard care (unsupervised lifestyle intervention) on
metabolic (body composition and insulin sensitivity), re-
productive (anti-müllerian hormone [AMH] and steroid
profiles) and mental health (depression and
health-related quality of life) in women with PCOS.
Methods/design
Hypothesis
Based on previous literature, we hypothesise that HIIT
will result in greater health outcomes such as greater in-
sulin sensitivity, increased lean muscle mass, decreased
androgens, increased sex hormone binding globulin and
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improved mental health, and health-related quality of life
compared to moderate intensity exercise or standard
care.
Design
We will employ a three-arm, parallel-group, RCT (Fig. 1)
and recruit 60 women diagnosed with PCOS from the
community and health clinics that are located in Mel-
bourne, Australia, via advertisement flyers in local
media, information boards in clinics and PCOS websites.
They will be randomised to undergo one of three
12-week supervised interventions: either HIIT, standard
supervised exercise (SSE), or standard care [Con] (un-
supervised lifestyle advice) with a 6-month and
12-month post-intervention follow-up for selected
endpoints.
Inclusion criteria
Women aged 18–45 years with a BMI greater than 25
kg.m2 and diagnosed with PCOS using the Rotterdam
criteria [25] will be recruited for this study. Their med-
ical practitioner will have previously diagnosed PCOS
and the research endocrinologist will confirm this prior
to participation in the study. Diagnosis of PCOS by the
Rotterdam criteria requires confirmation of two of the
following: (i) oligo- or anovulation; (ii) clinical (hirsutism
and acne) and/or biochemical hyperandrogenism; (iii)
polycystic ovaries on ultrasound and exclusion of other
causes of hyperandrogenism [25]. Features of PCOS will
be recorded to allow phenotyping as recommended by
the National Institutes of Health [26].
Exclusion criteria
Exclusion criteria will be other causes of menstrual dis-
turbance and hyperandrogenism, known cardiovascular
(cardiac arrhythmias), uncontrolled hypertension (resting
systolic blood pressure > 160mmHg and/or diastolic
blood pressure > 105mmHg), bleeding disorders, skin or
anaesthetic allergies, musculoskeletal injuries that may be
aggravated by the exercise protocol, pregnancy, type 1 or
2 diabetes or taking anti-hypertensive, insulin sensitising,
anti-obesity or hormonal contraceptive medications.
Screening
Prospective participants will be screened to check eligi-
bility and to assess potential risks of adverse events dur-
ing exercise. If identified as having multiple risk factors
(family history [first-degree] of cardiometabolic risk fac-
tors, chronic conditions [that do not exclude from par-
ticipation] but could interfere with testing or exercise, or
have a BMI > 40 kg.m2), exercise clearance will be re-
quired by their general practitioner. A member of the re-
search team will obtain written informed consent from
all participants prior to participation in the study.
Data monitoring
Details of procedures for data management have been
reviewed and approved by the Victoria University Human
Research Ethics Committee (reference HRE15–298). All
electronic data will be stored on password-protected com-
puters. Hard copies of any data will be kept in locked filing
cabinets in a secure office. All questionnaire data will be
de-identified.
Harms
All adverse events associated with the study will be re-
corded and be reported to the Victoria University Hu-
man Research Ethics Committee.
Auditing
No formal auditing process is proposed for the current
trial. The principal investigator, Professor Nigel Stepto,
has extensive experience as a lead research investigator
in numerous human clinical trials and is responsible for
the integrity of the current trial and [3, 12, 27].
Ethics
The study has been approved by the Victoria University
Human Research Ethics Committee (reference HRE15–
298) and is registered with the Australian New Zealand
Clinical Trials Registry (ACTRN12615000242527). Any
modifications or changes to the protocol will be pro-
vided in writing to the Victoria University Human Re-
search Ethics Committee for approval. The study
protocol was designed in accordance with the SPIRIT
checklist (Additional file 1). Reporting of the study will
follow the CONSORT statement [28].
Baseline assessment
Baseline assessment will involve three sessions. Two ses-
sions will be required to complete a symptom-limited
graded exercise protocol (the first session being a familiar-
isation of the test). In the 7 days preceding session three,
participants will wear an Actigraph™ accelerometer to es-
tablish levels of habitual physical activity. The third base-
line session will involve a muscle biopsy from the vastus
lateralis, an adipose tissue biopsy from the subcutaneous
abdominal tissue and a hyperinsulinemic-euglycemic
clamp. Participants will also undergo a dual x-ray absorp-
tiometry scan (DXA; GE Lunar iDXA) and be asked to
complete validated questionnaires to assess physical activ-
ity (International Physical Activity Questionnaire [IPAQ])
[29], quality of life (SF-36 & PCOSQ) [30, 31], depression,
anxiety and stress (Depression Anxiety Stress Scale
[DASS-21]) [32] and a 3-day food diary.
Randomisation and blinding
Following baseline testing, participants will be rando-
mised to one of three 12-week interventions; HIIT, SSE
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Fig. 1 SPIRIT flow diagram of randomised control trial. GXT graded exercise test, ECG electrocardiogram, Insulin clamp hyperinsulinemic-euglycemic
clamp, DXA dual energy x-ray absorptiometry, HIIT high intensity intermittent training, SSE supervised standard exercise, Con control
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or Con (details of the three treatment arms in Table 1).
An independent biostatistician will randomise subjects
by a simple randomisation procedure using compu-
terised sequence generation with an allocation ratio of
1:1:1. Two tables based on BMI (< 35 kg.m2 or > 35
kg.m2) will be created. As exercise interventions cannot
be blinded from participants and staff (accredited exer-
cise physiologists) implementing the intervention, only
staff undertaking sample analysis and endpoint data pro-
cessing will be blinded to group allocation.
Intervention
Every participant will receive a menstrual diary to moni-
tor menstrual cycles. As recommended by the Australian
evidence-based PCOS guidelines and International
evidence-based PCOS guidelines, all women will receive
evidence-based behaviour change coaching [9, 10] based
on social cognitive theory and the behaviour change
wheel [33]. This will involve a 2-h session including goal
setting and goal striving, education regarding the im-
portance of physical activity and healthy eating and edu-
cation on effectively using media and resources for
healthy eating and diet [34].
Exercise interventions
Exercise will be conducted on stationary bikes in an in-
dividual setting. Exercise intensities will be prescribed
and monitored using heart rates (percentage of heart
rate reserve [HRR]), as described in Table 1. Sessions
will be conducted at Victoria University fitness centres/
exercise clinics under the supervision of accredited exer-
cise physiologists [4, 12, 35–39]. Adherence and compli-
ance will be determined from supervised exercise
session attendance and completion of prescribed exer-
cise (duration and intensity [percentage HRR]), respect-
ively. Data from participants with less than 75%
adherence will be included in the intention to treat ana-
lysis only. Any musculoskeletal injuries or changes in
health status will be recorded via a provided web-based
diary.
Volume matching and training progression
The SSE and HIIT intervention arms will be matched
for training volume (metabolic equivalent task (MET).-
min/week) and progressed weekly by manipulating ses-
sion duration and intensity. Both SSE and HIIT will
progress from 312 MET.min/week in week 1 to 530
MET.min/week in weeks 6–12, meeting exercise guide-
lines [40]. Exercise sessions will include warm-up and
cool down protocols, and will be adjusted weekly to in-
dividual capabilities and training adaptations [4, 41]. See
Table 1 for details.
Preventing and managing injury
Absolute risk of cardiovascular disease in this young fe-
male population is low. However, participants will be
screened with appropriate clinical monitoring during all
exercise testing (ECG) and training sessions (heart rate
and blood pressure monitoring) with individualised
training prescription and progression reducing the risks
of injuries and adverse events [4, 12, 35, 36].
Post-intervention assessment
Within 4 days after the final exercise session (HIIT or
SSE) or following 12 weeks (Con) the hyperinsulinemic-
euglycemic clamp, questionnaires (SF-36, PCOSQ, IPAQ
and DASS-21), muscle and fat biopsies, body compos-
ition measures (DXA, weight, waist and hip circumfer-
ences) and graded exercise tests will be repeated.
Women will be asked to abstain from training or phys-
ical exercise during this period. An accelerometer will be
given (or mailed if in the control group) 7 days before
post-intervention testing to assess exercise in this period.
They will again be asked to complete a 3-day food dairy.
Follow-up
Six and 12 months after completion of the 12-week
intervention phase, women will return to study centres
for re-assessment of selected endpoints (mental health,
health-related quality of life and physical activity ques-
tionnaires) to determine whether participants continued
Table 1 Details of the three treatment arms
Intervention Details
Con Standard care consisting of basic exercise advice (150min/week) with no supervised or structured exercise. We do not anticipate the
control group will engage in a significant amount of exercise compared to their baseline physical activity levels without the addition
of a structured exercise program [11]
SSE group Minimum physical activity recommendations (150 min per week) [40], in three supervised 50-min sessions/week of continuous
moderate intensity exercise sessions of cycling at 50–60% HRR (~ 3.5 METs)
HIIT group Minimum vigorous physical activity recommendations (~ 75min per week) [40], in three supervised sessions/week of HIIT exercise
(cycling/running). Based on existing literature, pilot data [43] and patient consultation, we will use a practical weekly training program
encompassing two successful HIIT protocols [16, 17, 55]: two sessions/week of short constant load cycling of 12 × 1min at > 85% HRR
(> 9 METs; [1 min HIIT]) with 1 min active recovery; one session/week of cycling 6–8 × 4 min at > 85% HRR (> 9 METS; [4 min HIIT]) with
2 min active recovery
Con control- standard care, SSE supervised standard exercise, HIIT high-intensity intermittent training, min minutes, MET metabolic equivalent task, HRR heart
rate reserve
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healthy lifestyle behaviours after the conclusion of the
intervention.
Outcome measurements
Outcome measures will be taken pre-intervention and
post-intervention (Fig. 1). The primary outcome is the
change in insulin sensitivity (measured by the steady
state glucose infusion rate determined during the
hyperinsulinemic-euglycemic clamp) between the
three interventions. Secondary outcomes include re-
productive health via hormone profiles (AMH and
steroid profiles), mental health and health-related
quality of life, body composition, physical activity be-
haviours and cardio-respiratory fitness.
Data collection and analysis
Anthropometric assessment
Following an overnight fast, participants will be weighed
lightly clothed and without shoes (HW-PW200, associ-
ated scales services). Height will be taken without shoes
using a calibrated stadiometer (Proscale Inductive Series
I, Accurate Technology Inc.) and BMI calculated [weight
(kilograms)/height squared (squared metres)]. Waist and
hip circumference measurements will be taken [42] and
the waist to hip ratio calculated. Fat mass, abdominal fat
mass and fat free mass will be assessed using DXA
(iDXA GE Lunar Prodigy scanner) and analysed by a
qualified operator.
Fitness parameters
Cardiorespiratory fitness via peak oxygen uptake
(VO2peak) will be assessed using a symptom-limited
graded exercise protocol on a cycle-ergometer [43]. The
test will start after a 5-min period at rest. The protocol
will consist of three 3-min stages at an intensity of 25
watts (W), 50W and 75W, respectively, and then an in-
crease by 25W every minute. The test will be termi-
nated objectively when:
 Participant can no longer sustain a pedal rate greater
than 60 rpm
 There is no longer a change in VO2 with increasing
work rate
 Respired expiratory rate reaches 1.1 or greater
 Appearance of clinical signs or symptoms of
metabolic or cardiorespiratory abnormalities
 Patient wishes to stop
Expired respiratory gases will be collected by the
COSMED cardio pulmonary exercise test system
breath-by-breath connected to automated gas analysers.
The system will be calibrated before conducting each test
using Hans Rudolph syringe and gases of known O2 and
CO2 content (BOC gas). As a precautionary measure,
12-lead ECG will be monitored to minimise adverse
events from undiagnosed cardiac arrhythmias during this
testing.
Physical activity and diet
Physical activity and exercise before baseline testing and
before post-intervention testing will be monitored by a tri-
axial accelerometer (Actigraph™) for 7 continuous days.
Average daily time spent in moderate to vigorous activity
and METs will be calculated by the Freedson VM3 (2011)
algorithms in Actlife software [44]. During the 12-week
intervention habitual physical activity will be objectively
assessed continuously using physical activity monitors
(FitBit Flex™) and a smart phone application. Dietary
habits will be assessed by a consecutive 3-day food diary
before baseline and post-intervention testing. Food diaries
will be analysed by FoodWorks® (Xyris) for the major food
groups (grains, fruit, vegetables, protein and dairy), total
energy and macronutrients.
Self-reported measures
Participants will monitor their menstrual cycles using a
menstrual diary, which will be used to assess menstrual
cyclicity throughout the study. Self-reported physical ac-
tivity questionnaires (IPAQ) [29] will be used to assess
physical activity behaviour pre- and post-intervention.
Mental health and health-related quality of life measures
will be completed pre- and post-intervention to identify
any changes in mental health and wellbeing after an ex-
ercise intervention and to determine the relationship
with other outcome measures (DASS, SF-36 and
PCOSQ) [30, 32, 45].
Hyperinsulinemic-euglycemic clamp
Participants will undergo a hyperinsulinemic-euglycemic
clamp to measure insulin sensitivity [3, 46, 47]. Human
insulin (NovoNordisk ActRapid) will be infused at a con-
stant rate (40 mU/min/m2) while a variable rate glucose
solution is infused to meet the target of 5 mmol.L− 1
blood glucose in the last 30 min of the clamp. During
the clamp, one hand will be warmed to improve blood
flow for blood sampling. Blood samples will be taken
every 5 min to monitor circulating blood glucose and an
additional blood sample will be taken every 30min dur-
ing the clamp for insulin analysis. To reduce the risk of
low potassium levels (hypokalaemia), participants will be
given a single dose (600 mg) of slow-release potassium
before the commencement of the insulin clamp.
Pathology analysis
Glucose will be measured using an automated analyser
(YSI 2300 STAT Plus). Insulin and N-terminal
pro-peptide of type I and III collagen (collagen synthesis
biomarkers) concentrations will be determined by
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radioimmunoassay according to manufacturer instruc-
tions (HI-14 K, EMD Millipore, UniQ PIIINP RIA
#68570, UniQ PINP RIA #67034, Orion Diagnostica).
Standard clinical pathology testing, including lipid pro-
files, haemoglobin A1c (HbA1c) and AMH, will be per-
formed by a health pathology service. Serum steroid
profiles, including testosterone, dihydrotestosterone, 3α
and 3β androstanediols, estradiol, estrone, dehydroepi-
androsterone (DHEA), androstenedione and progester-
one, will be determined by liquid chromatography–mass
spectrometry. Enzyme-linked immunosorbent assay
(ELISA) will be used to measure transforming growth
factor beta 1/3 (TGFβ1/3). To minimize variability, sam-
ples will be stored at (− 80 °C) and batch analysed by a
single laboratory.
Tissue biopsies
Vastus lateralis muscle and peri-umbilical fat biopsies
will be carried out by a medical practitioner under local
anaesthesia. After a local anaesthetic (1% xylocaine) is
injected under the skin, a small incision is made to ac-
cess the thigh muscle or peri-umbilical fat tissue and a
small amount of each tissue is extracted from a consist-
ent depth using a Bergstrom biopsy needle with suction
[46]. Tissue samples will be used for the determination
of DNA methylation profiles and protein levels of key
tissue fibrosis molecules, insulin signalling proteins and
TGFβ ligands before and after the 12-week intervention
by western blotting.
Western blotting
Protein levels of key tissue fibrosis molecules, insulin
signalling proteins and TGFβ ligands will be measured
by western blotting. Protein extraction and western blot-
ting will be performed as previously described [27].
Global methylation of peripheral blood mononuclear cell
populations
Detailed methodology of peripheral blood mononuclear
cell (PBMC) isolation and quantification has previously
been described [48]. Briefly PBMCs will be isolated and
collected by centrifugation by Ficoll gradient, before be-
ing stained for flow cytometry. A specific gating strategy
to analyse T-helper cells, T cytotoxic cells, B cells and
monocytes will be used to analyse the 5-methylcytosine
quantity in each immune cell population.
Statistical methods and determination of sample size
Primary analyses will be undertaken on an
intention-to-treat basis, including all participants as ran-
domised, regardless of treatment actually received. The
HIIT group will be compared with the SSE and Con
groups using a planned contrast of change from baseline
to the week 12 endpoint on the basis of insulin sensitivity
scores using a mixed-model repeated measures analysis.
Stratification variables will be evaluated and retained in
analyses where they are measured as significant or
quasi-significant. Transformation of scores, including cat-
egorisation, may be undertaken to meet distributional as-
sumptions and accommodate outliers. Comparisons of
changes in insulin sensitivity scores from baseline to other
time points will be undertaken as secondary analyses. Data
will be analysed by SPSS and significance will be accepted
when p < 0.05. Where required p values from the statis-
tical analysis will be adjusted for multiple comparisons
using the false discovery rate [49] and statistical signifi-
cance will be accepted when false discovery rate q < 0.1.
Using the primary outcome of change in insulin
sensitivity (as measured by the glucose infusion rate)
of 27 mg/min/m2 (effect size (Cohens d) = 0.25) in re-
sponse to training [4], we require a total of 42 participants
or n = 14 per group to achieve a power of 85% (α = 0.05).
With an approximate attrition rate of 30% based on previ-
ous research, we will recruit 60 participants [4, 12].
Discussion
PCOS is under-recognised by health professionals and
leaves women on track for a plethora of chronic condi-
tions ranging from anxiety and depression to diabetes,
subfertility, cardiovascular disease and stroke [1, 50–52].
Despite affecting around one million Australian women
and costing over $800 million nationally each year [10,
53, 54], there are no optimal treatments.
Overall, HIIT in PCOS promises greater metabolic ben-
efits with demonstrated acceptability and safety [23]. It
has the potential to address general and PCOS-specific
barriers (low confidence and physical limitations) to
standard exercise participation [14, 15]. However, evidence
from prospective studies comparing volume-matched
HIIT and standard moderate exercise for efficacy and en-
joyment is lacking in women generally and more import-
antly in women at high risk of metabolic disease (i.e.
PCOS).
Here, we describe the protocol of a study evaluating
the effectiveness and mechanistic impacts of a practical
allied health supervised 12-week HIIT or moderate in-
tensity exercise program on cardiometabolic, reproduct-
ive and mental health in overweight women with PCOS.
This trial aims to demonstrate comparative efficacy of
different exercise protocols to inform vital large-scale
clinical trials and ultimately best clinical practice in
treatment of PCOS. It will advance the understanding of
PCOS management by providing insights into the best
exercise intensities to improve insulin sensitivity. Further
helping to address the limitations highlighted by the re-
cently released international guidelines in PCOS lifestyle
management [9]. Finally, we will explore the impact of
different exercise protocols on reproductive health
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(anti-müllerian hormone and steroid profiles), mental
health and health-related quality of life and molecular
mechanisms that affect insulin resistance. The impact of
this work is likely to be significant due to the unprece-
dented public health challenge of PCOS in young Aus-
tralian women for which we currently have no optimal
treatment.
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